Oncology Corporate Profile
| 6.3700 | |
| -0.2500 |
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.
Website: http://www.clovisoncology.com/
| Brand | Generic | Indication |
|---|---|---|
| Rubraca® | rucaparib | Rubraca® is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA approved companion diagnostic for RUBRACA. |
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| rucaparib | PARP inhibitor (oral) | Ovarian cancer | III | |
| rucaparib | PARP inhibitor (oral) | Prostate cancer | III | |
| rucaparib | PARP inhibitor (oral) | Breast cancer | II | |
| lucitanib | tyrosine kinase inhibitor | Breast cancer | II | Servier |
| rucaparib | PARP inhibitor (oral) | Gastric cancer | II | |
| rucaparib | PARP inhibitor (oral) | Ovarian cancer | II | |
| rucaparib | PARP inhibitor (oral) | Prostate cancer | II | |
| rucaparib | PARP inhibitor (oral) | Triple negative Breast cancer | II | |
| lucitanib (+ fulvestrant) | tyrosine kinase inhibitor | Breast cancer | I | Servier |
View additional information on product candidates here »
Follow @OBRTweets